PCSK9 inhibitors reduce Lp(a) by an average of 27%, according to a recent meta-analysis of randomized controlled trials.
Statin-intolerant? Options include ezetimibe, bempedoic acid, inclisiran, PCSK9 antibodies
Louis lists the main alternatives for people who cannot tolerate statins: ezetimibe, bempedoic acid, inclisiran, Repatha and Praluent. Hashtags point to trials such as CLEAR Outcomes, FOURIER and ORION, but no details are given.


